IL-SELIG-GROUP
1.12.2021 14:47:12 CET | Business Wire | Press release
Selig Group (“Selig”), owned by CC Industries (“CCI”), announced today that it has acquired Manufacture Générale de Joints (“MGJ”). Founded in 1947 and headquartered near Lyon, France, MGJ is a leading supplier of foam-based liners worldwide. Through decades of investment, MGJ has developed differentiated foam-based products for an expansive range of applications. The combination provides Selig with highly complementary adjacent capabilities to serve its customers more broadly on a global basis and will accelerate the combined development of environmentally sustainable products. This is Selig’s second acquisition in the last year and reflects its strategy to augment growth and expand its business model via complementary solutions.
“MGJ is an excellent company and shares Selig’s passion for developing technically-differentiated solutions to customers' problems,” said Bill Crown, President and Chief Executive Officer of CCI. “We look forward to supporting Selig’s continued growth globally and welcome MGJ’s team into the Selig family.”
Steve Cassidy, President and Chief Executive Officer of Selig added, “MGJ’s team, products, markets and capabilities are extremely complementary to Selig and represent a significant growth opportunity for the combined organization. Our cultures are well-aligned and focused on developing unique and valuable solutions for customers' packaging issues.”
Stéphane Triquet, of MGJ, will become a Vice President within Selig’s European business unit. Mr. Triquet stated, “Selig is an ideal long-term home for MGJ’s employees and owner to support our operation in its next phase of growth. This is a highly strategic combination, enabling us to provide a more comprehensive solutions offering for customers globally. We will continue to focus on the innovative, high-quality products and the exemplary service our customers rely upon.”
As part of the acquisition, MGJ will adopt the Selig Group name to reflect one team and a focus on growing the combined business. The business will continue to operate from its primary facility in France.
About Selig Group (www.seligsealing.com )
Selig Group is a leading global provider of innovative packaging solutions. The company is the leading global supplier of innovative, technically differentiated container sealing and venting solutions for food, beverage, pharmaceutical, healthcare, personal care and industrial applications. Selig also manufactures a range of technical laminates and flexible packaging products in Europe for these applications. The company’s products are designed to serve customers’ needs for ensuring freshness, providing packaging integrity, extending shelf life, providing tamper evidence, expanding in e-commerce and protecting brand identity. Selig is headquartered in Naperville, Illinois, USA with manufacturing and distribution locations worldwide.
About MGJ (www.mgj.com )
MGJ is the technology leader in foam-based container sealing solutions worldwide. The company provides an expansive product range of closure liners for wine, spirits, pharmaceutical, personal care, food, household and industrial markets. Over its history, MGJ has grown by developing innovative product constructions and providing reliable and consistent quality and service to customers. The company serves a global customer base from operations in France, Canada and China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
